A detailed history of Geode Capital Management, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,883,199 shares of AVXL stock, worth $16.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,883,199
Previous 1,831,253 2.84%
Holding current value
$16.3 Million
Previous $7.73 Million 38.42%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.11 - $7.04 $213,498 - $365,699
51,946 Added 2.84%
1,883,199 $10.7 Million
Q2 2024

Aug 09, 2024

BUY
$3.39 - $5.02 $401,803 - $595,000
118,526 Added 6.92%
1,831,253 $7.73 Million
Q1 2024

May 13, 2024

BUY
$4.55 - $6.75 $215,501 - $319,700
47,363 Added 2.84%
1,712,727 $8.72 Million
Q4 2023

Feb 13, 2024

BUY
$5.04 - $9.95 $465,675 - $919,340
92,396 Added 5.87%
1,665,364 $15.5 Million
Q3 2023

Nov 13, 2023

BUY
$6.55 - $9.37 $200,875 - $287,359
30,668 Added 1.99%
1,572,968 $10.3 Million
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $684,972 - $849,509
89,422 Added 6.15%
1,542,300 $12.5 Million
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $394,484 - $557,114
47,414 Added 3.37%
1,452,878 $12.5 Million
Q4 2022

Feb 13, 2023

BUY
$7.65 - $14.43 $608,450 - $1.15 Million
79,536 Added 6.0%
1,405,464 $13 Million
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $121,983 - $176,259
13,706 Added 1.04%
1,325,928 $13.7 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $32,054 - $56,303
4,385 Added 0.34%
1,312,222 $13.1 Million
Q1 2022

May 13, 2022

BUY
$9.74 - $17.69 $101,938 - $185,143
10,466 Added 0.81%
1,307,837 $16.1 Million
Q4 2021

Feb 11, 2022

BUY
$16.88 - $23.31 $1.68 Million - $2.31 Million
99,262 Added 8.28%
1,297,371 $22.5 Million
Q3 2021

Nov 12, 2021

BUY
$16.82 - $25.75 $681,832 - $1.04 Million
40,537 Added 3.5%
1,198,109 $21.5 Million
Q2 2021

Aug 13, 2021

BUY
$10.16 - $28.86 $1.24 Million - $3.52 Million
121,887 Added 11.77%
1,157,572 $26.5 Million
Q1 2021

May 12, 2021

BUY
$5.17 - $16.13 $1.25 Million - $3.9 Million
242,093 Added 30.51%
1,035,685 $15.5 Million
Q4 2020

Feb 12, 2021

BUY
$4.01 - $7.58 $171,527 - $324,234
42,775 Added 5.7%
793,592 $4.29 Million
Q3 2020

Nov 13, 2020

BUY
$3.8 - $5.0 $114,349 - $150,460
30,092 Added 4.18%
750,817 $3.42 Million
Q2 2020

Aug 13, 2020

BUY
$2.62 - $5.2 $8,237 - $16,348
3,144 Added 0.44%
720,725 $3.55 Million
Q1 2020

May 14, 2020

BUY
$2.38 - $5.81 $248,619 - $606,924
104,462 Added 17.04%
717,581 $2.26 Million
Q4 2019

Feb 13, 2020

BUY
$2.31 - $3.14 $56,066 - $76,210
24,271 Added 4.12%
613,119 $1.59 Million
Q3 2019

Nov 12, 2019

BUY
$2.22 - $3.9 $82,328 - $144,631
37,085 Added 6.72%
588,848 $1.86 Million
Q2 2019

Aug 14, 2019

BUY
$2.75 - $3.7 $613,016 - $824,785
222,915 Added 67.79%
551,763 $1.86 Million
Q1 2019

May 14, 2019

BUY
$1.68 - $3.42 $61,992 - $126,198
36,900 Added 12.64%
328,848 $1 Million
Q4 2018

Feb 13, 2019

BUY
$1.25 - $2.75 $4,608 - $10,139
3,687 Added 1.28%
291,948 $455,000
Q3 2018

Nov 13, 2018

BUY
$2.23 - $3.82 $15,957 - $27,335
7,156 Added 2.55%
288,261 $786,000
Q2 2018

Aug 14, 2018

SELL
$2.08 - $4.26 $92,522 - $189,493
-44,482 Reduced 13.66%
281,105 $736,000
Q1 2018

May 15, 2018

BUY
$2.32 - $3.44 $16,397 - $24,313
7,068 Added 2.22%
325,587 $898,000
Q4 2017

Feb 13, 2018

BUY
$3.12 - $4.94 $24,148 - $38,235
7,740 Added 2.49%
318,519 $1.03 Million
Q3 2017

Nov 14, 2017

BUY
$3.42 - $4.87 $38,635 - $55,016
11,297 Added 3.77%
310,779 $1.29 Million
Q2 2017

Aug 14, 2017

BUY
N/A
299,482
299,482 $1.59 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.